Siliq Probably Isn't The Light At The End Of Valeant's Tunnel
Executive Summary
Valeant is touting Siliq to lead new product growth, but the drug's significant safety concerns in a competitive psoriasis market likely will offset efficacy advantages it could offer.
You may also be interested in...
A Renewal Begins For Bausch (Née Valeant), But Challenges Ahead
The company reported a second quarter of organic sales growth, though revenues declined because of divestitures. Dermatology and Diversified Products segments continued to face challenges, and the company is working to respond to an FDA CRL for potential new dermatology product Duobrii.
Valeant Claims Progress, Asks Investors For Patience
The Canadian specialty pharma has exceeded its near-term debt-reduction goals, but are its plans for a return to growth grounded in reality? Market analysts recommend caution, but see some reason for optimism.
Valeant Sees Sunshine On Cloudy Day, But Dermatology Recovery Just Starting
The Bausch & Lomb and Salix units are gaining sales momentum, execs said, while debt-reduction efforts remain ahead of schedule. They offered no excuses for a declining dermatology franchise, however.